

***Listing of the Claims***

The listing of claims will replace all prior versions, and listings of claims in the application.

1 - 34. (Cancelled)

35. (Currently amended) A method for the treatment ~~or prevention~~ of neuroectodermal tumors, malignant astrocytomas, or glioblastomas, said method comprising administering to an animal in need thereof an antisense oligonucleotide which is complementary to an NTP mRNA sequence corresponding to nucleotides 150-1139 of SEQ ID NO:1.

36. (Cancelled)

37. (Previously presented) The method of claim 35, wherein said antisense oligonucleotide is a 15 to 40 mer.

38. (Previously presented) The method of claim 35, wherein said antisense oligonucleotide is selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11.

39. (Previously presented) The method of claim 35, wherein said antisense oligonucleotide is deoxyribonucleic acid.

40. (Previously presented) The method of claim 35, wherein said antisense oligonucleotide is a deoxyribonucleic acid phosphorothioate.

41. (Previously presented) The method of claim 35, wherein said antisense oligonucleotide is a derivative of a deoxyribonucleic acid or a derivative of a deoxyribonucleic acid phosphorothioate.

42. (Previously presented) The method of claim 35, wherein said antisense oligonucleotide is administered to said animal as part of a pharmaceutically acceptable carrier.

43. (Currently amended) A method for the treatment ~~or prevention~~ of neuroectodermal tumors, malignant astrocytomas, or glioblastomas, said method comprising administering to an animal in need thereof a ribozyme comprising a target sequence which is complementary to an NTP mRNA sequence corresponding to nucleotides 150-1139 of SEQ ID NO:1.

44. (Cancelled)

45. (Previously presented) The method of claim 43, wherein said ribozyme is administered to said animal as part of a pharmaceutically acceptable carrier.

46 - 52. (Cancelled)